NO20055015L - T-type calcium kanalblokkere - Google Patents

T-type calcium kanalblokkere

Info

Publication number
NO20055015L
NO20055015L NO20055015A NO20055015A NO20055015L NO 20055015 L NO20055015 L NO 20055015L NO 20055015 A NO20055015 A NO 20055015A NO 20055015 A NO20055015 A NO 20055015A NO 20055015 L NO20055015 L NO 20055015L
Authority
NO
Norway
Prior art keywords
calcium channel
type calcium
nr16r17
cr7r8
cr5r6
Prior art date
Application number
NO20055015A
Other languages
English (en)
Other versions
NO20055015D0 (no
Inventor
Yukinori Masuda
Taiji Furukawa
Original Assignee
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Ind Ltd filed Critical Nissan Chemical Ind Ltd
Publication of NO20055015D0 publication Critical patent/NO20055015D0/no
Publication of NO20055015L publication Critical patent/NO20055015L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Det tilveiebringes en blokkerer av T-type-kalsiumkanalen, hvilken blokkerer er en optisk aktiv 1,4-dihydropyridin-forbindelse, et farmasøytisk akseptabelt salt derav eller et solvat derav, med formel (1) hvor R1 og R2 uavhengig av hverandre er en C1-6-alkylgruppe, eller R1 og R2 danner sammen -CR5R6-CR7R8-, -CR5R6-CR7R8-CR9R10- eller -CR5R6-CR7R8-CR9R10-CR11R12- osv; X1 og X2 uavhengig av hverandre er O eller NR13; Ar er en valgfritt substituert fenylgruppe osv; Ra og Rb uavhengig av hverandre er en C1-6-alkylgruppe, -L2-NR16R17, CH2O-L2-NR16R17, CN, -L2-N(CH2CH2) 2NR16 eller NR16R17 osv; Y er en C1-20-alkylgruppe, -L3-NR18R19, og * er den absolutte konfigurasjon R.
NO20055015A 2003-03-28 2005-10-27 T-type calcium kanalblokkere NO20055015L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003090916 2003-03-28
JP2003393893 2003-11-25
PCT/JP2004/004432 WO2004087172A1 (ja) 2003-03-28 2004-03-29 Ｔ型カルシウムチャネル阻害剤

Publications (2)

Publication Number Publication Date
NO20055015D0 NO20055015D0 (no) 2005-10-27
NO20055015L true NO20055015L (no) 2005-11-15

Family

ID=33134293

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055015A NO20055015L (no) 2003-03-28 2005-10-27 T-type calcium kanalblokkere

Country Status (11)

Country Link
US (1) US7563782B2 (no)
EP (1) EP1609504A4 (no)
JP (1) JP4539862B2 (no)
KR (1) KR100870527B1 (no)
AU (1) AU2004226547B2 (no)
CA (1) CA2520628C (no)
NO (1) NO20055015L (no)
NZ (1) NZ542681A (no)
RU (1) RU2326886C2 (no)
TW (1) TW200503733A (no)
WO (1) WO2004087172A1 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100749843B1 (ko) * 2006-07-13 2007-08-21 한국과학기술연구원 Ｔ-타입 칼슘 채널에 억제 활성을 지닌 신규2,4-디옥소-퀴나졸린 유도체 및 이의 제조방법
JP2010526073A (ja) * 2007-05-02 2010-07-29 ティーエーユー・セラピューティクス・エルエルシー 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体
WO2008138126A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
US9427429B2 (en) 2010-03-01 2016-08-30 Tau Therapeutics Llc Cancer diagnosis and imaging

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59161392A (ja) * 1983-03-04 1984-09-12 Nippon Shinyaku Co Ltd ジヒドロピリジン誘導体及びその製法
JPS6069089A (ja) 1983-09-26 1985-04-19 Nissan Chem Ind Ltd ジヒドロピリジン−５−ホスホネ−ト誘導体およびその製造法
JPS6163688A (ja) 1984-08-03 1986-04-01 Nissan Chem Ind Ltd ジヒドロピリジン−５−ホスホン酸環状エステル類
JPS6130591A (ja) 1984-07-20 1986-02-12 Nissan Chem Ind Ltd ジヒドロピリジン−５−ホスホネ−ト誘導体
JPS60248693A (ja) 1984-04-19 1985-12-09 Nippon Shinyaku Co Ltd ピリジン誘導体及び製法
JPS60258194A (ja) 1984-06-01 1985-12-20 Otsuka Pharmaceut Factory Inc ジヒドロピリジン誘導体
JPS6137793A (ja) 1984-07-31 1986-02-22 Nissan Chem Ind Ltd ジヒドロピリジン−２−アミノ−５−ホスホネ−ト誘導体
JPS61210092A (ja) * 1985-03-14 1986-09-18 Nissan Chem Ind Ltd ジヒドロピリジン−５−ホスホン酸ジアミド誘導体
MW2586A1 (en) 1985-04-26 1987-12-09 Hoffmann La Roche 1,3-disubstituted imidazolium salts
JPS61254596A (ja) * 1985-05-02 1986-11-12 Nissan Chem Ind Ltd ジヒドロピリジン−５−ホスホン酸エチレンエステル類
JPH0655751B2 (ja) 1986-01-22 1994-07-27 日産化学工業株式会社 ジヒドロピリジンホスホン酸環状エステル
US4885284A (en) 1986-01-22 1989-12-05 Nissan Chemical Industries Ltd. Dihydropyridine-5-phosphonic acid cyclic propylene ester
UA5590A1 (uk) * 1986-01-23 1994-12-28 Ніссан Кемікал Індастріз Лтд Спосіб одержання пропіленглікового ефіру заміщеної 1,4-дігідропіріділ-5-фосфорної кислоти, або його фармацевтично прийнятной солі або сольвата
JPH0678349B2 (ja) 1986-01-23 1994-10-05 日産化学工業株式会社 ジヒドロピリジン−５−ホスホン酸エステル類
JPH0615553B2 (ja) * 1986-02-20 1994-03-02 日産化学工業株式会社 ジヒドロピリジン−５−ホスホンアミド酸類
JPH0755955B2 (ja) 1986-09-10 1995-06-14 日産化学工業株式会社 光学活性なジヒドロピリジン−５−ホスホン酸エステル
JPH01113398A (ja) 1987-10-28 1989-05-02 Nissan Chem Ind Ltd 光学活性なジヒドロピリジン−５−ホスホン酸エステル
JPH01275591A (ja) 1988-04-27 1989-11-06 Nissan Chem Ind Ltd ジヒドロピリジン−５−ホスホン酸誘導体
JPH0211592A (ja) * 1988-06-29 1990-01-16 Nissan Chem Ind Ltd 光学活性なジヒドロピリジンホスホン酸エステル
FR2672890A1 (fr) 1991-02-20 1992-08-21 Inst Investigacion Desarrol Derives de 2,6-dimethyl-4-(4'-hydroxy-3',5'-di-t-butylphenyl)-1,4-dihydropyridine, leur procede de preparation et leur utilisation comme capteurs de radicaux libres.
SI9200344B (sl) 1992-11-26 1998-06-30 Lek, Postopek za pripravo amlodipin benzensulfonata
GB9916076D0 (en) * 1999-07-08 1999-09-08 Smithkline Beecham Plc Novel compounds
JP2003504373A (ja) * 1999-07-12 2003-02-04 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド オキサチエピノ［６，５−ｂ］ジヒドロピリジン類、並びに関連組成物および方法

Also Published As

Publication number Publication date
WO2004087172A1 (ja) 2004-10-14
AU2004226547B2 (en) 2008-10-23
JP4539862B2 (ja) 2010-09-08
EP1609504A4 (en) 2010-07-21
TW200503733A (en) 2005-02-01
CA2520628A1 (en) 2004-10-14
TWI339581B (no) 2011-04-01
NO20055015D0 (no) 2005-10-27
CA2520628C (en) 2012-08-14
KR100870527B1 (ko) 2008-11-26
RU2005133221A (ru) 2006-05-10
AU2004226547A1 (en) 2004-10-14
NZ542681A (en) 2009-01-31
US7563782B2 (en) 2009-07-21
EP1609504A1 (en) 2005-12-28
US20070010490A1 (en) 2007-01-11
KR20050119162A (ko) 2005-12-20
RU2326886C2 (ru) 2008-06-20
JPWO2004087172A1 (ja) 2006-06-29

Similar Documents

Publication Publication Date Title
AR025976A1 (es) Inhibidores de fab i.
CO5251397A1 (es) Inhibidores de fab i
NO20062517L (no) 2-cyanopyrrolidinkarboksamidforbindelse
NO20033848L (no) Nitrogenholdige heteroarylforbindelser med en HIV integrase inhiberende aktivitet
NO20064077L (no) Kemokinreseptorantagonister
NO20053246L (no) Kondensert 1,3-dihydroimidazol-ringforbindelse.
DK1485359T3 (da) Natriumkanalblokkere
DE60317198D1 (de) Proteinkinaseinhibitoren
ATE457025T1 (de) Kinaseinhibitoren
HRP20020175B1 (en) N-heterocyclikc derivatives as nos inhibitors
NO20082077L (no) Spirosykliske quinazolinderivater som PDE7-inhibitorer
WO2007016392A3 (en) Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
NO20051577L (no) Azaaren-derivater
AR047339A1 (es) Derivados de difenilazetidona.proceso de obtencion.
NO20052580L (no) Blandinger for behandling av infeksjon av Flavivirida viruser
NO20070368L (no) Virale polymeraseinhibitorer
DK1385515T3 (da) Spiropyrazole forbindelser
NO331012B1 (no) N-sulfonyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
NO20063330L (no) Amidderivater med en syklopropylaminokarbonylsubstituent som er nyttige som cytokininhibitorer
PT1167355E (pt) Forma cristalina de celecoxib
DK1531672T3 (da) Antimikrobielle sammensætninger
NO20055015L (no) T-type calcium kanalblokkere
NO20061832L (no) Karboksamidderivat av amidtype
NO20050612L (no) Pyrrolidinderivater som oksytocinantagonister
DE60014043D1 (de) Flouride von 4-substituierten piperidin-derivaten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application